TARS Relative Valuation
TARS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TARS is overvalued; if below, it's undervalued.
Historical Valuation
Tarsus Pharmaceuticals Inc (TARS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 110.02. The fair price of Tarsus Pharmaceuticals Inc (TARS) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：81.29
Fair
97.42
PE
1Y
3Y
5Y
Trailing
Forward
70.99
EV/EBITDA
Tarsus Pharmaceuticals Inc. (TARS) has a current EV/EBITDA of 70.99. The 5-year average EV/EBITDA is 3.40. The thresholds are as follows: Strongly Undervalued below -81.62, Undervalued between -81.62 and -39.11, Fairly Valued between 45.91 and -39.11, Overvalued between 45.91 and 88.42, and Strongly Overvalued above 88.42. The current Forward EV/EBITDA of 70.99 falls within the Overvalued range.
70.49
EV/EBIT
Tarsus Pharmaceuticals Inc. (TARS) has a current EV/EBIT of 70.49. The 5-year average EV/EBIT is -1.67. The thresholds are as follows: Strongly Undervalued below -88.89, Undervalued between -88.89 and -45.28, Fairly Valued between 41.94 and -45.28, Overvalued between 41.94 and 85.55, and Strongly Overvalued above 85.55. The current Forward EV/EBIT of 70.49 falls within the Overvalued range.
5.38
PS
Tarsus Pharmaceuticals Inc. (TARS) has a current PS of 5.38. The 5-year average PS is 18.24. The thresholds are as follows: Strongly Undervalued below -8.63, Undervalued between -8.63 and 4.80, Fairly Valued between 31.67 and 4.80, Overvalued between 31.67 and 45.10, and Strongly Overvalued above 45.10. The current Forward PS of 5.38 falls within the Historic Trend Line -Fairly Valued range.
40.11
P/OCF
Tarsus Pharmaceuticals Inc. (TARS) has a current P/OCF of 40.11. The 5-year average P/OCF is -24.76. The thresholds are as follows: Strongly Undervalued below -194.29, Undervalued between -194.29 and -109.53, Fairly Valued between 60.01 and -109.53, Overvalued between 60.01 and 144.77, and Strongly Overvalued above 144.77. The current Forward P/OCF of 40.11 falls within the Historic Trend Line -Fairly Valued range.
92.68
P/FCF
Tarsus Pharmaceuticals Inc. (TARS) has a current P/FCF of 92.68. The 5-year average P/FCF is 51.86. The thresholds are as follows: Strongly Undervalued below -443.13, Undervalued between -443.13 and -195.63, Fairly Valued between 299.36 and -195.63, Overvalued between 299.36 and 546.85, and Strongly Overvalued above 546.85. The current Forward P/FCF of 92.68 falls within the Historic Trend Line -Fairly Valued range.
Tarsus Pharmaceuticals Inc (TARS) has a current Price-to-Book (P/B) ratio of 10.37. Compared to its 3-year average P/B ratio of 4.92 , the current P/B ratio is approximately 110.96% higher. Relative to its 5-year average P/B ratio of 3.93, the current P/B ratio is about 163.67% higher. Tarsus Pharmaceuticals Inc (TARS) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -9.79%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -6.96% , the current FCF yield is about -100.00% lower.
10.37
P/B
Median3y
4.92
Median5y
3.93
-1.66
FCF Yield
Median3y
-9.79
Median5y
-6.96
Competitors Valuation Multiple
The average P/S ratio for TARS's competitors is 0.00, providing a benchmark for relative valuation. Tarsus Pharmaceuticals Inc Corp (TARS) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 146.68%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of TARS increased by 47.79% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 48.12M to 118.70M.
The secondary factor is the P/E Change, contributed -20.67%to the performance.
Overall, the performance of TARS in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Tarsus Pharmaceuticals Inc (TARS) currently overvalued or undervalued?
What is Tarsus Pharmaceuticals Inc (TARS) fair value?
How does TARS's valuation metrics compare to the industry average?
What is the current P/B ratio for Tarsus Pharmaceuticals Inc (TARS) as of Dec 05 2025?
What is the current FCF Yield for Tarsus Pharmaceuticals Inc (TARS) as of Dec 05 2025?
What is the current Forward P/E ratio for Tarsus Pharmaceuticals Inc (TARS) as of Dec 05 2025?